Friday, March 15, 9:00am

Microenvironmental Determinants of Systemic Therapy Response in Kidney Cancer: from human to mouse and back

featuring

A. Ari Hakimi, MD
Associate Professor; Co-Leader, Translational Kidney Cancer Program, Memorial Sloan Kettering Cancer Center

55 Park Street Auditorium | Zoom Access
Continental breakfast will be available

Needs: There is a need for novel RCC biomarkers, RCC models, and novel immunotherapies to treat RCC.

Objectives: Understand new immunocompetent RCC models, novel treatment strategies, and biomarkers for RCC immune response.

Dr. Hakimi is a urologic surgeon whose focus is on the care of patients with urologic malignancies, especially kidney tumors. He received his medical degree from Albert Einstein College of Medicine and completed fellowship at Memorial Sloan Kettering Cancer Center.

His research aims to understand immune infiltration, inflammation, and the tumor microenvironment in RCC to identify novel therapeutic targets to overcome resistance to systemic therapies. These studies apply bulk, single-cell and spatial RNA sequencing, flow cytometry, and immunogenomic analyses to both patient samples and novel, immunocompetent kidney cancer mouse lines that his lab has developed.